Research programme: synthetic hepatitis B DNA vaccine - Aldevron/CytoGenixAlternative Names: Synthetic HBV DNA vaccine - Aldevron/ Cytogenix
Latest Information Update: 08 Jun 2010
At a glance
- Originator Aldevron LLC; CytoGenix
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 01 Sep 2005 Preclinical trials in Hepatitis B in USA (unspecified route)